Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) EBITDA: 2018-2024

Historic EBITDA for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to -$8.6 million.

  • Pharming Group N.V's EBITDA rose 2096.11% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.8 million, marking a year-over-year increase of 442.95%. This contributed to the annual value of -$8.6 million for FY2024, which is 60.03% down from last year.
  • According to the latest figures from FY2024, Pharming Group N.V's EBITDA is -$8.6 million, which was down 60.03% from -$5.4 million recorded in FY2023.
  • Pharming Group N.V's 5-year EBITDA high stood at $76.3 million for FY2020, and its period low was -$8.6 million during FY2024.
  • Over the past 3 years, Pharming Group N.V's median EBITDA value was -$5.4 million (recorded in 2023), while the average stood at $1.4 million.
  • Its EBITDA has fluctuated over the past 5 years, first spiked by 34.45% in 2022, then plummeted by 129.55% in 2023.
  • Pharming Group N.V's EBITDA (Yearly) stood at $76.3 million in 2020, then crashed by 82.22% to $13.6 million in 2021, then spiked by 34.45% to $18.2 million in 2022, then plummeted by 129.55% to -$5.4 million in 2023, then tumbled by 60.03% to -$8.6 million in 2024.